A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

  • End date
    Jan 30, 2022
  • participants needed
  • sponsor
Updated on 23 September 2020
Eric Hedrick, MD
Primary Contact
Subei People's Hospital (2.0 mi away) Contact
+204 other location
squamous cell carcinoma


The purpose of this study is to evaluate the efficacy and safety of Tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic ESCC.

Treatment Capecitabine, cisplatin, Placebo, Paclitaxel, Oxaliplatin, Fluorouracil (5-Fu), tislelizumab, Platinum (cisplatin or oxaliplatin) + Fluorouracil (5-FU), Platinum (cisplatin or oxaliplatin) + capecitabine, Platinum (cisplatin or oxaliplatin) + paclitaxel
Clinical Study IdentifierNCT03783442
Last Modified on23 September 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Squamous cell carcinoma or Esophageal Cancer or Esophageal Squamous Cell Carcinoma?
Pathologically (histologically) confirmed diagnosis of ESCC
Stage IV unresectable ESCC at first diagnosis OR unresectable, locally advanced recurrent or metastatic disease with a treatment free interval of at least 6 months after definitive treatment

Exclusion Criteria

Palliative radiation treatment for ESCC within 4 weeks of study treatment initiation
Prior systemic therapy for unresectable, locally advanced recurrent or metastatic ESCC
Received prior therapies targeting programmed cell death protein-1 (PD-1), programmed cell death protein ligand-1 (PD-L1) or PD-L2
Participants with evidence of fistula (either esophageal/bronchial or esophageal/aorta)
Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention (clinically significant recurrence requiring an additional intervention within 2 weeks of intervention)
Evidence of complete esophageal obstruction not amenable to treatment
Unintentional weight loss 5% within one month prior to randomization or Nutritional Risk Index (NRI) < 83.5 per investigator's choice
Locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy per local investigator
Participants with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is 500 IU/mL or participants with active hepatitis C virus (HCV)
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet